LQDA's recent 9.0% one-month return and bullish news sentiment have pushed its composite score to 59/100, but the stock's forward P/E of 7.2 and rev growth of 3055% suggest a disconnect between growth expectations and valuation. With a short interest of 17.2% and a target price of $51, the options market is pricing in an expected move of ~35% over the next 12 months, with two covered stock purchase (CSP) opportunities presenting a potential catalyst. The key risk is whether Liquidia's pulmonary drugs can meet analyst optimism, or if insider stock sales and sector competition from AZN and Sanofi will pressure the stock.
Composite
59
/ 100
1M
+9.0%
3M
+8.6%
6M
+69.9%
1Y
+158.2%
Trend
UP
Sharpe
0.15
Fundamentals
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap
$3B
Fwd P/E
7.2
Beta
0.56
Short Interest
17.2%
Analyst Target
$51
Margin
-44%
Rev Growth
3055%
ROE
-111%
D/E
442%
From 52w High
-19.6%
From 52w Low
+233.3%
Consensus
Buy
Research Digest
Liquidia's (LQDA) Chief Commercial Officer sold 80,000 shares for $2.8M under a pre-arranged trading plan, while Wells Fargo raised its price target to $51 from $44, citing optimism around the company's pulmonary hypertension therapies. LQDA has a forward P/E of 7.2, with a 3055% revenue growth estimate. The market may be mispricing potential risks around insider selling and competition from AstraZeneca's efzimfotase alfa and Sanofi's Rezurock.